Clear Search

Showing 1 result for “Siovitz L” published 2024.

July 2024

Efficacy and safety of upadacitinib or elsubrutinib alone or in combination for systemic lupus erythematosus: A Phase 2 randomized controlled trial

Arthritis Rheumatol 2024 DOI: 10.1002/art.42926 Epub ahead of print

Daily oral upadacitinib 30 mg and ABBV-599 high dose (elsubrutinib 60 mg QD + upadacitinib 30 mg) were effective in multiple outcome measures including disease activity, flares, time to first flare, and joint counts.

more…